Equibles does not estimate personal net worth.
Earlier roles on record: CFO and Chief Accounting Officer at Biocryst Pharmaceuticals Inc (BCRX) until April 9, 2025. Biocryst Pharmaceuticals Inc reported in an 8-K filed April 10, 2025 that Anthony Doyle resigned as Interim Principal Accounting Officer, effective April 9, 2025. Biocryst Pharmaceuticals Inc reported in an 8-K filed April 10, 2025 that Anthony Doyle resigned as Chief Financial Officer and Interim Principal Accounting Officer, effective April 9, 2025. Biocryst Pharmaceuticals Inc reported in an 8-K filed March 4, 2025 that Anthony Doyle resigned as Chief Financial Officer, effective April 9, 2025. The proxy statement of Biocryst Pharmaceuticals Inc reports total compensation of $2,141,135 for Anthony Doyle in fiscal 2025, including a base salary of $151,925. Disclosed compensation is on record for 6 fiscal years. Anthony Doyle has spoken on 20 earnings calls across 1 company, most recently for Biocryst Pharmaceuticals Inc on February 24, 2025. The companies whose calls Anthony Doyle spoke on are classified in the Healthcare sector.
“on February 28, 2025, Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025 (the “Effective Date”).”
“on February 28, 2025, Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025 (the “Effective Date”).”
“At the beginning of last year, we laid out our goals for strong commercial growth for Orladeo, advancing our early pipeline into the clinic, and moving towards sustainable and meaningful profitability in the short term.”
“It's great to see that, in addition to ORLADEYO having another really impressive quarter, we are also making significant progress on the development side, all while continuing along our path to profitability.”
“It's very encouraging to see yet another really strong quarter for ORLADEYO. It's great work by the whole team. You can find detailed second quarter financials in today's earnings press release.”
“You can find our detailed first quarter financials in today's earnings press release, and I'd like to call your attention to a few items. Total revenue for the quarter was $92.8 million, $88.9 million of which came from ORLADEYO with the remaining $3.9 million coming from RAPIVAB sales.”
“It was great to see such a strong Q4 and full-year 2023 for ORLADEYO. Not just the revenue performance, but the continued underlying strength in net new patient adds, giving us confidence of achieving between $380 million and $400 million in global ORLADEYO revenue this year on our path to peak sales of $1 billion.”
2023-07-10–2025-04-09
Start not stated–2025-04-09
Drug Manufacturers - Specialty & Generic · Healthcare
CFO, Chief Accounting Officer
2023-07-10–2025-04-09
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Biocryst Pharmaceuticals Inc (BCRX) | Former Chief Financial Officer and Treasurer | $151,925 | $2,141,135 |
| 2024 | Biocryst Pharmaceuticals Inc (BCRX) | Former Chief Financial Officer and Treasurer | $549,429 | $3,287,271 |
| 2023 | Biocryst Pharmaceuticals Inc (BCRX) | Former Chief Financial Officer and Treasurer | $528,297 | $1,790,349 |
| 2022 | Biocryst Pharmaceuticals Inc (BCRX) | Former Chief Financial Officer and Treasurer | $507,978 | $2,281,851 |
| 2021 | Biocryst Pharmaceuticals Inc (BCRX) | Chief Financial Officer and Treasurer | $490,800 | $2,890,803 |
| 2020 | Biocryst Pharmaceuticals Inc (BCRX) | Chief Financial Officer and Treasurer | $345,455 | $4,117,930 |
